Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Dose, Two-Period, Open Label, Dose Determination, Randomized, Cross-Over Study of CTAP201 Injection and Doxercalciferol (Hectorol) Injection in Subjects With Stage 5 CKD and SHPT on Hemodialysis

NCT00792857 is registered in ClinicalTrials.gov with OPKO IP Holdings II, Inc. as lead sponsor.

NCT NCT00792857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00792857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Dose, Two-Period, Open Label, Dose Determination, Randomized, Cross-Over Study of CTAP201 Injection and Doxercalciferol (Hectorol) Injection in Subjects With Stage 5 CKD and SHPT on Hemodialysis
Lead sponsor
OPKO IP Holdings II, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2008
Completion date
October 31, 2009
Enrollment
24 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, chronic renal failure, chronic renal insufficiency, secondary hyperparathyroidism